Egis | biosimilar

Keyword: biosimilar

Agreement for Biosimilar Candidates in Key Central and Eastern European Markets

• mAbxience and Egis collaborate on the commercialization of two biosimilar candidates • The agreement covers eight Central and Eastern European countries with the potential for expansion into additional territories • mAbxience will serve as the marketing authorization holder, while Egis will manage commercialization in the designated regions

Active Agent Production Renewed

By renewing our active agent base, we wish to simultaneously raise the rate of our active agents produced internally in a reliable quality and at a competitive price as well as to increase our exports.

Channels

Egis World